<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CONTEXT: High plasmatic <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels have been associated with arterial and <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The C677T <z:chebi fb="13" ids="29357,29358">methylene</z:chebi> <z:chebi fb="0" ids="20506,26907">tetrahydrofolate</z:chebi> reductase (MTHFR) gene mutation is one of the known causes for high <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels in plasma </plain></SENT>
<SENT sid="2" pm="."><plain>Anticardiolipin antibody (ACA) is also associated with <z:mp ids='MP_0005048'>thrombosis</z:mp> and, along with other clinical complications such as <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent abortion</z:e> and <z:hpo ids='HP_0003826'>stillbirth</z:hpo>, is part of the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN: Case report </plain></SENT>
<SENT sid="4" pm="."><plain>CASE REPORT: A 19-year-old woman with two gestations and one parity (G2P1) had exhibited <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> in her previous puerperal period </plain></SENT>
<SENT sid="5" pm="."><plain>Investigation of thrombophilic factors revealed ACA-IgM and heterozygous C677T mutation in the MTHFR gene </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, protein C, protein S and <z:hpo ids='HP_0001976'>antithrombin III deficiencies</z:hpo>, and Leiden factor V and the G20210A mutation in the prothrombin gene, were not detected </plain></SENT>
<SENT sid="7" pm="."><plain>The patient received 55,000 IU of subcutaneous <z:chebi fb="5" ids="28304">heparin</z:chebi> daily, from the 15th to the 36th week of pregnancy, when vaginal delivery took place </plain></SENT>
<SENT sid="8" pm="."><plain>There were no clinical complications during the puerperal period and she was discharged three days after delivery, while still using oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> </plain></SENT>
</text></document>